A Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus High-dose Therapy With Melphalan and Autologous Stem Cell Transplantation, Followed by Consolidation With KRd, and Maintenance With Lenalidomide and Dexamethasone in Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Trial Profile

A Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus High-dose Therapy With Melphalan and Autologous Stem Cell Transplantation, Followed by Consolidation With KRd, and Maintenance With Lenalidomide and Dexamethasone in Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Lenalidomide; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2015 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
    • 18 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top